Compare PETS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PETS | MDXH |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 41.1M |
| IPO Year | 2003 | 2021 |
| Metric | PETS | MDXH |
|---|---|---|
| Price | $1.85 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 195.7K | ★ 1.3M |
| Earning Date | 06-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | $2.98 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.51 |
| 52 Week High | $4.10 | $5.33 |
| Indicator | PETS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 17.40 |
| Support Level | $1.62 | $0.51 |
| Resistance Level | $2.41 | $3.78 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 33.56 | 11.07 |
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.